An Open Label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY79-4620 Administered as an Intravenous Infusion Once Every 2 Weeks in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2013
At a glance
- Drugs BAY 794620 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 27 Sep 2012 New trial record